Ethical Allocation of Remdesivir

American Journal of Bioethics 20 (7):84-86 (2020)
  Copy   BIBTEX

Abstract

As the federal government distributed remdesivir to some of the states COVID-19 hit hardest, policymakers scrambled to develop criteria to allocate the drug to their hospitals. Our state, Michigan, was among those states to receive an initial quantity of the drug from the U.S. government. The disparities in burden of disease in Michigan are striking. Detroit has a death rate more than three times the state average. Our recommendation to the state was that it should prioritize the communities that bear a disproportionate burden of suffering in the allocation of the new potential treatment. This recommendation is justified not only for new drugs with uncertain effects, but also for drugs of certain benefit or vaccines. For states with significant health disparities, such as Michigan, this allocation priority may help to repair them. In fact, any other allocation strategy may make them worse

Author Profiles

Tyler Gibb
Western Michigan University School Of Medicine
Parker Crutchfield
Western Michigan University School Of Medicine

Analytics

Added to PP
2020-06-11

Downloads
398 (#39,698)

6 months
105 (#32,161)

Historical graph of downloads since first upload
This graph includes both downloads from PhilArchive and clicks on external links on PhilPapers.
How can I increase my downloads?